AI-healthcare startup OpenEvidence has raised $200 million in a Series C funding round, pushing its valuation to an estimated $6 billion, as it accelerates development of its clinician-facing AI platform.
Glimpse:
Founded in 2022, OpenEvidence has developed an AI-powered platform that assists doctors by summarizing and retrieving medical evidence quickly. The Series C injection led by prominent VC firms including Google Ventures and new backers such as Blackstone brings its total funding to nearly $500 million and values the business at about $6 billion.
OpenEvidence, a fast-growing healthcare AI startup, has announced that it has raised $200 million in a Series C funding round, bringing its valuation to approximately $6 billion. Founded in 2022, the company focuses on enabling clinicians to access, interpret and act on medical evidence through a combination of search, ranking, retrieval and generative AI tools. The platform is designed to help physicians access reliable, evidence-based information during patient encounters, support clinical-trial matching and summarise scientific literature.
The recent investment round was led by investors including Google Ventures, and included participation from Sequoia Capital, Kleiner Perkins, Thrive, Coatue, Blackstone and more. With this new infusion, OpenEvidence says its technology now supports millions of clinical consultations each month and is used in over ten thousand hospitals and medical centres in the U.S. The co-founder, Dr. Daniel Nadler, commented that developing high-performance medical AI spanning natural language processing, computer vision and domain-specific ranking models requires substantial compute and data investment.
The startup says it experienced a sharp growth trajectory: usage surged by 60 % since July, and usage among doctors and nurses reportedly increased 830 % year-on-year. It states that in the current year, more than 100 million Americans will be treated by a clinician using its platform. These figures highlight how quickly its tools are being adopted in clinical workflows.
Looking ahead, OpenEvidence plans to expand its partnerships with medical publishers, increase its model capabilities to interpret charts, tables and complex scientific figures, and extend into additional therapeutic areas and geographies. It sees its Series C funding as a launchpad for scaling globally and deepening its clinical integration.
“Our work spans both natural language processing and computer vision, since we also train proprietary models to interpret and rank figures and tables from scientific papers. Each new generation of models compounds this cost, reflecting the true price of developing medical superintelligence.”
By
HB Team
